Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/20—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems

Definitions

• Neutrophils constitute the first line of cellular defense in response to bacterial and fungal infections (1) and rely on granular proteins to kill microorganisms.
• uncontrolled secretion of granular proteins by neutrophils is injurious to the host.
• Increased plasma levels of neutrophil secretory proteins, including myeloperoxidase (MPO) and elastase are associated with tissue damage and are hallmarks of endotoxemia and sepsis and are also observed in sterile trauma, leading to systemic inflammatory response syndrome.
• MPO myeloperoxidase
• elastase elastase
• Neutrophil-derived plasma MPO predicts endothelial dysfunction (2) and is an indicator of the onset of sepsis (3).
• MPO is also involved in the pathogenesis of cardiovascular disease and arthritis (4), (5).
• secreted neutrophil elastase is implicated in the development of acute respiratory distress syndrome (6) and tissue damage through the release of proteolytic enzyme
• Neutrophils contain four secretory organelles that engage sequentially in exocytosis depending on stimuli strength (9), (10).
• a site of infection where high concentrations of pathogens are present, neutrophil secrete specific and azurophilic granules, which contain the most toxic neutrophil cargos.
• neutrophils under pathological conditions encounter a variety of stimuli capable of inducing exocytosis in circulation, resulting in high levels of neutrophil secreted proteases and pro-oxidative factors that are associated with systemic inflammation.
• the present disclosure provides small molecule compounds that are potent inhibitors (“Inhibitors”) of the interaction between the small GTPase Rab27a and its effector JFC1, which are two central regulators of neutrophil exocytosis.
• Inhibitors or pharmaceutically acceptable salts thereof, that are of Formula (I):
• R 1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Ci-C 6 -alkyl-O-(Ci-C 6 -alkyl), -Ci-C 6 -alkenyl, -Ci-C 6 -alkoxyl, -NRR’, -C(O)R, C 3 - Cs-cycloalkyl, and -Ce-Cio-aryl.
• any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo.
• X is -NR X (R 2 ) or Ci-Ce-alkyl.
• R x is H or Ci-Ce-alkyl.
• R 2 is selected from the group consisting of:
• Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof.
• Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof.
• Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, -O-Ce- Cw-aryl, -C(0)-C 6 -Cio-aryl, -C(0)NH-C 6 -Cio-aryl, -S(0)o-2-C 6 -Cio-aryl, -(Ci-C 6 -alkyl)-(0)o- i-(Ce-Cio-aryl), -C(O)NRR’, -C(O)OR, 5-
• Any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety in Het or Cy is substituted by 1 to 3 substituents selected from the group consisting of halo, -CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-Ce- alkyl)(Ce-Cio-aryl).
• R and R’ is independently selected from H and Ci-Ce-alkyl.
• R and R’ together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S).
• the present disclosure also provides in embodiments a pharmaceutical composition
• a pharmaceutical composition comprising one or more Inhibitors or a pharmaceutically acceptable salt thereof as described herein and a pharmaceutically acceptable carrier.
• the present disclosure provides a method for treating a disease in a subject suffering therefrom, wherein the disease is one selected from those described herein.
• the method comprises administering to the subject one or more Inhibitors or pharmaceutically acceptable salt thereof as described herein.
• FIGS. 1A-B illustrates the cellular activities of the Inhibitors.
• FIG. 1A illustrates the mechanism of exocytosis of a neutrophil granule’s cargo.
• FIG. IB illustrates the point of inhibition of granule exocytosis by the Inhibitors.
• FIGS. 2A-G are schematics of a molecular docketing analysis of the Inhibitors on Rab27a.
• FIG. 2A is a three-dimensional model of the Inhibitor Nexinhib 20 bound inside a binding pocket of Rab27a.
• FIG. 2B illustrates the specific Rab27a amino acid interactions with Nexinhib 20.
• FIG. 2C illustrates the specific Rab27a amino acid interactions with the Inhibitor Cl.
• FIG. 2D illustrates the specific Rab27a amino acid interactions with the Inhibitor C2.
• FIG. 2E illustrates the specific Rab27a amino acid interactions with the Inhibitor C4.
• FIG. 2F illustrates the specific Rab27a amino acid interactions with the Inhibitor C5.
• FIG. 2G illustrates the specific Rab27a amino acid interactions with the Inhibitor C6.
• FIGS. 3A-C illustrate the effect of the Inhibitors of Rab27a on MPO secretion of mouse and human neutrophils.
• FIG. 3A is a schematic representation of a cell-based chemiluminescence-based exocytosis assay used for the identification of cell-active Inhibitors of MPO secretion.
• FIG. 3B is a graph showing the effect of the Inhibitors of Rab27a on MPO secretion in purified mouse neutrophils.
• FIG. 3C is a graph of a dose-response analysis of the Inhibitor Cl using the chemiluminescence-based exocytosis assay.
• FIG. 4 is a flow cytometry analysis of the effect of the Inhibitors on the mobilization of azurophilic granules in human neutrophils.
• FIG. 5 is a flow cytometry analysis of the effect of the Inhibitors on the exocytosis of specific granules in human neutrophils.
• FIG. 6 is a graph showing the effect of the Inhibitors on the exocytosis of Gelatinase granule cargo MMP9 in human neutrophils.
• FIG. 7 is a graph showing the effect of the Inhibitors on the exocytosis of secretory vesicles and the upregulation of the adhesion molecule CDl lb at the plasma membrane in human neutrophils.
• FIG. 8A-C New neutrophil exocytosis inhibitors (NEIa-) Cl, C4 and C6 inhibit the hyperactivation of secretion induced by the Nlrp3A350V mutation (purple, •), compared to wild-type controls (black symbols).
• Gasdermin D is inactive and so, exacerbated secretion is mediated by the Nlrp3 activation in a neutrophil intrinsic manner.
• A gelatinase (MMP9) granules
• B azurophilic granules (MPO, myeloperoxidase)
• C CD63 (an endolysosomal marker).
• FIG. 9A-F A) Compund NEIa-C6 (C6) inhibits neutrophil mediated inflammation in vivo, in a model of cryopyrin-associated periodic syndrome. Nlrp3 ⁇ 50N ere ERT2 and control mice were injected i.p. with 50 mg/kg tamoxifen followed by C6 (30mg/Kg) or vehicle as described. B) Total leukocytes numbers and subtypes were not affected. C) Animals suffer weight loss with disease progression. D) The activation of circulating neutrophils is attenuated by C6.
• C6 Compund NEIa-C6
• E The percentage of immature (pro-inflammatory, Ly6G-) neutrophils in circulation (blood) in Nlrp3 350N is attenuated by treatment with C6 (4.29%) as compared to vehicle (11.0%).
• F Neutrophilic infiltration into the kidney measured as total MMP9 and MPO levels is significantly decreased in C6 treated mice.
• the protection was specific for kidneys.
• FIG. 10A-B Treatment with compound NEIa-C6 inhibits pro-inflammatory cytokine production in a model of sepsis.
• mice receive NEIa-C6 (30mg/Kg) orvehicleby a single i.p. injection and two hours later, the animals are challenged with a single i.p. injection of lipopolysaccharide (LPS, 8 mg/Kg) or PBS (vehicle for LPS).
• LPS lipopolysaccharide
• PBS vehicle for LPS
• FIG. 11A-B A, Docking analysis of NEI20 compound reveals pockets in Rab27a (green) for potential substitution and extension of the selected hits.
• B Structures and scores of NEI20 and NEIa-C6 analog.
• FIG. 12 Structure and scores of newly designed analogs with modifications and substitutions in C3 or CIO.
• the Inhibitors of the present disclosure are potent small molecule inhibitors of neutrophil exocytosis of specific and azurophilic granules, and are therefore useful, in various embodiments, as therapeutics for treating inflammatory processes including sepsis, arthritis, cardiovascular disease, acute lung injury, glomerulonephritis, autoimmune disorders and cancer.
• the present disclosure satisfies needs in the art for therapies that reduce high levels of neutrophil proteases and pro-oxidative secretions associated with systemic inflammation, but without affecting other important innate immune responses, including phagocytosis and neutrophil extracellular trap (NET) production.
• NET neutrophil extracellular trap
• Compounds of the present disclosure target the interaction between the small GTPase Rab27a and its effector JFC1, two central regulators of neutrophil exocytosis which fulfills the desired activities of inhibiting exocytosis of azurophilic and specific granules and superoxide production without impairing other innate immune responses of neutrophils.
• the compounds are therefore of robust utility in treating various diseases associated with systemic neutrophil-dependent inflammation.
• the Inhibitors of the present disclosure decrease neutrophil secretion of their most toxic granules without affecting other aspects of the neutrophil innate immune response.
• the Inhibitors decrease neutrophil infiltration into tissues in vivo, supporting the use of these compounds as systemic anti-inflammatory agents in many neutrophil-mediated pathological processes including coronary artery disease, autoinflammatory disease, sepsis, arthritis, ischemiareperfusion injury, acute lung injury, glomerulonephritis, autoimmune disorders and cancer.
• Rab27a and JFC1 proteins regulates the intracellular trafficking, docking, fusion, and exocytosis of neutrophil specific and azurophilic granules which are the most toxic neutrophil cargoes.
• Rab27a and JFC1 proteins are dispensable for other innate immune-related neutrophil functions, including phagocytosis (11) and NET production (12).
• Exocytosis of specific and azurophilic granules is dependent on JFC1 binding to Rab27a because mutation of tryptophan 83 of the TGDWF domain of JFC1 abolishes JFC1-Rab27a binding and inhibits secretion (13).
• JFC1 is one of eleven Rab27a effectors, and it is essential in neutrophils but dispensable for other cells.
• the Inhibitors of the present disclosure are specific for JFC1 (neutrophils).
• Rab27a and its effector molecules play fundamental roles in the modulation of the neutrophil inflammatory response by controlling cellular release of inflammatory proteinases and oxidative factors, including myeloperoxidase (14, 15).
• knocking out either Rab27a or JFC1 decreases plasma levels of neutrophil secretory proteins, reduces tissue infiltration by neutrophils, and increases survival in a mouse model of endotoxin-induced systemic inflammation (16).
• JFC1 nor Rab27a regulate trafficking of azurophilic granules to the phagosome (17, 11)
• the Inhibitors interfering with the Rab27a- JFC1 binding have similar anti-inflammatory properties without affecting other neutrophil innate immune functions.
• FIG. 1 A the inhibition of neutrophil exocytosis of specific and azurophilic granules by the Inhibitors disclosed herein is illustrated.
• Exocytosis occurs by recruitment of a granule from the neutrophil cytoplasm to the cell membrane, which is dependent on actin cytoskeleton remodeling and microtubule assembly. This is followed by granule tethering and docking to the cell membrane, leading to contact of the outer surface of the lipid bilayer membrane surrounding the granule with the inner surface of the target membrane.
• Granule priming then follows to make granules fusion-competent to ensure that they fuse with the target membrane rapidly, and a reversible fusion pore structure develops between the granule and the target membrane. Granule fusion occurs by the expansion of the fusion pore, leading to complete fusion of the granule with the target membrane to release granular contents.
• the small GTPase Rab27a regulates azurophilic granule exocytosis (15).
• Rab27a Using mouse neutrophils deficient in Rab27a (Rab27 ash/ash ⁇ these knockout neutrophils have a decreased number of azurophilic granules near the plasma membrane and impaired azurophilic granule exocytosis. Exocytosis of secretory vesicles in Rab27-deficient neutrophils was functional, indicating that Rab27 GTPases selectively control the exocytosis of neutrophil granules. Rab27a regulates exocytosis through interaction with specific effector molecules, including JFC1.
• JFC1 regulates docking of secretory granules by bridging the Rab27a-containing vesicles and the plasma membrane through interaction with both Rab27a and with plasma membrane phosphatidylinositol 1,4,5- trisphosphate.
• the Inhibitors disclosed herein inhibit Rab27a-JFC1 binding and neutrophil exocytosis.
• Alkyl refers to straight or branched chain hydrocarbyl including from 1 to about 20 carbon atoms.
• an alkyl can have from 1 to 10 carbon atoms or 1 to 6 carbon atoms.
• Exemplary alkyl includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like, and also includes branched chain isomers of straight chain alkyl groups, for example without limitation, -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH3) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH(CH
• halogen refers to -F or fluoro, -Cl or chloro, -Br or bromo, or -I or iodo.
• alkenyl refers to straight or branched chain hydrocarbyl groups including from 2 to about 20 carbon atoms having 1-3, 1-2, or at least one carbon to carbon double bond. An alkenyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
• Alkyne or alkynyl refers to a straight or branched chain unsaturated hydrocarbon having the indicated number of carbon atoms and at least one triple bond.
• Examples of a (C2-Cs)alkynyl group include, but are not limited to, acetylene, propyne, 1- butyne, 2-butyne, 1 -pentyne, 2-pentyne, 1 -hexyne, 2-hexyne, 3 -hexyne, 1 -heptyne, 2- heptyne, 3 -heptyne, 1 -octyne, 2-octyne, 3 -octyne and 4-octyne.
• An alkynyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
• alkoxy refers to an -O-alkyl group having the indicated number of carbon atoms.
• a (Ci-Ce)-alkoxy group includes -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-butyl, -O- ec-butyl, -O-/c/7-butyl, -O-pentyl, -O-isopentyl, -O- neopentyl, -O-hexyl, -O-isohexyl, and -O-neohexyl.
• cycloalkyl refers to a saturated monocyclic, bicyclic, tricyclic, or polycyclic, 3- to 14-membered ring system, such as a Cs-Cs-cycloalkyl.
• the cycloalkyl may be attached via any atom.
• Representative examples of cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• Polycyclic cycloalkyl includes rings that can be fused, bridged, and/or spiro-fused.
• a cycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
• Aryl when used alone or as part of another term means a carbocyclic aromatic group whether or not fused having the number of carbon atoms designated or if no number is designated, up to 14 carbon atoms, such as a Ce-Cio-aryl or Ce-Cu-aryl.
• aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like (see e.g. Lang’s Handbook of Chemistry (Dean, J. A., ed) 13 th ed. Table 7-2 [1985]).
• Aryl also contemplates an aryl ring that is part of a fused polycyclic system, such as aryl fused to cycloalkyl as defined herein.
• An exemplary aryl is phenyl.
• An aryl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
• Cargo refers to the microbicidal and cytotoxic contents of neutrophil granules including myeloperoxidase (MPO), elastase, lactoferrin, and matrix metalloproteinases.
• MPO myeloperoxidase
• elastase elastase
• lactoferrin elastase
• matrix metalloproteinases elastase
• Exocytosis also known as degranulation in neutrophils, refers to the regulated release at the cell surface of pre-formed cytotoxic proteins from neutrophil granules, which can include myeloperoxidase (MPO), elastase, lactoferrin, and matrix metalloproteinases, which possess potent antimicrobial activity but are also highly cytotoxic.
• MPO myeloperoxidase
• elastase elastase
• lactoferrin lactoferrin
• matrix metalloproteinases which possess potent antimicrobial activity but are also highly cytotoxic.
• heteroatom refers to N, O, and S. Compounds of the present disclosure that contain N or S atoms can be optionally oxidized to the corresponding N-oxide, sulfoxide, or sulfone compounds.
• Heteroaryl alone or in combination with any other moiety described herein, is a monocyclic aromatic ring structure containing 5 to 10, such as 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, such as 1-4, 1-3, or 1-2, heteroatoms independently selected from the group consisting of O, S, and N. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or heteroatom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced.
• heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadi azolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, and indolyl.
• a heteroaryl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
• Heterocycloalkyl is a saturated or partially unsaturated non-aromatic monocyclic, bicyclic, tricyclic or polycyclic ring system that has from 3 to 14, such as 3 to 6, atoms in which 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N.
• Polycyclic heterocycloalkyl includes rings that can be fused, bridged, and/or spiro-fused.
• a heterocycloalkyl is optionally fused with aryl or heteroaryl of 5-6 ring members, and includes oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
• heterocycloalkyl groups include without limitation morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzofuryl, and dihydroindolyl.
• a heterocycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
• nitrile or “cyano” can be used interchangeably and refers to a -CN group.
• a “hydroxyl” or “hydroxy” refers to an -OH group.
• the Inhibitors described herein can exist in various isomeric forms, including configurational, geometric, and conformational isomers, including, for example, cis- or trans- conformations.
• the Inhibitors may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers.
• the term “isomer” is intended to encompass all isomeric forms of the Inhibitors of this disclosure, including tautomeric forms of the Inhibitors.
• the Inhibitors of the present disclosure may also exist in open-chain or cyclized forms. In some cases, one or more of the cyclized forms may result from the loss of water.
• composition of the open-chain and cyclized forms may be dependent on how the compound is isolated, stored or administered.
• the Inhibitors may exist primarily in an open-chained form under acidic conditions but cyclize under neutral conditions. All forms are included in the disclosure.
• Some Inhibitors described herein can have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms.
• An Inhibitor as described herein can be in the form of an optical isomer or a diastereomer. Accordingly, the disclosure encompasses compounds and their uses as described herein in the form of their optical isomers, diastereoisomers and mixtures thereof, including a racemic mixture.
• Optical isomers of the Inhibitors of the disclosure can be obtained by known techniques such as asymmetric synthesis, chiral chromatography, simulated moving bed technology or via chemical separation of stereoisomers through the employment of optically active resolving agents.
• stereoisomer means one stereoisomer of an Inhibitor that is substantially free of other stereoisomers of that compound.
• a stereomerically pure Inhibitor having one chiral center will be substantially free of the opposite enantiomer of the Inhibitor.
• a stereomerically pure Inhibitor having two chiral centers will be substantially free of other diastereomers of the Inhibitor.
• a typical stereomerically pure Inhibitor comprises greater than about 80% by weight of one stereoisomer of the Inhibitor and less than about 20% by weight of other stereoisomers of the Inhibitor, for example greater than about 90% by weight of one stereoisomer of the Inhibitor and less than about 10% by weight of the other stereoisomers of the Inhibitor, or greater than about 95% by weight of one stereoisomer of the Inhibitor and less than about 5% by weight of the other stereoisomers of the Inhibitor, or greater than about 97% by weight of one stereoisomer of the Inhibitor and less than about 3% by weight of the other stereoisomers of the Inhibitor, or greater than about 99% by weight of one stereoisomer of the Inhibitor and less than about 1% by weight of the other stereoisomers of the Inhibitor.
• the stereoisomer as described above can be viewed as composition comprising two stereoisomers that are present in their respective weight percentages described herein.
• the depicted structure controls. Additionally, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. In some cases, however, where more than one chiral center exists, the structures and names may be represented as single enantiomers to help describe the relative stereochemistry. Those skilled in the art of organic synthesis will know if the Inhibitors are prepared as single enantiomers from the methods used to prepare them.
• an Inhibitor is inclusive in that it encompasses an Inhibitor or a pharmaceutically acceptable salt, stereoisomer, and/or tautomer thereof.
• an Inhibitors of Formula I includes a pharmaceutically acceptable salt of a tautomer of the Inhibitor.
• a “pharmaceutically acceptable salt” is a pharmaceutically acceptable, organic or inorganic acid or base salt of an Inhibitor described herein.
• Representative pharmaceutically acceptable salts include, e.g., alkali metal salts, alkali earth salts, ammonium salts, water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylre
• treat refers to the amelioration or eradication of a disease or symptoms associated with a disease.
• the terms refer to minimizing or slowing the spread, progression, or worsening of the disease resulting from the administration of one or more prophylactic or therapeutic Inhibitors described herein to a patient with such a disease.
• prevent refers to the prevention of the onset, recurrence, or spread of the disease in a patient resulting from the administration of one or more Inhibitors described herein.
• an effective amount refers to an amount of an Inhibitor as described herein or other active ingredient sufficient to provide a therapeutic or prophylactic benefit in the treatment or prevention of a disease or to delay or minimize symptoms associated with a disease.
• a therapeutically effective amount with respect to an Inhibitor as described herein means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease. Used in connection with an Inhibitor as described herein, the term can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of or is synergistic with another therapeutic agent.
• a “patient” or subject” includes an animal, such as a human, cow, horse, sheep, lamb, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig.
• the animal is a mammal such as a non-primate and a primate (e.g., monkey and human).
• a patient is a human, such as a human infant, child, adolescent or adult.
• the terms “patient” and “subject” are used interchangeably.
• the present disclosure provides an Inhibitor of Formula (I), a tautomer, or a pharmaceutically acceptable salt thereof:
• R 1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Ci-C6-alkyl-O-(Ci-Ce-alkyl), -Ci-Ce-alkenyl, -Ci-Ce-alkoxyl, -NRR’, - C(O)R, Cs-Cs-cycloalkyl, and -Ce-Cio-aryl.
• any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo.
• X is -NR X (R 2 ) or Ci-Ce-alkyl.
• R x is H or Ci-Ce-alkyl.
• R 2 is selected from the group consisting of:
• Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof.
• Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof.
• Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, -O-Ce- Cw-aryl, -C(0)-C 6 -Cio-aryl, -C(0)NH-C 6 -Cio-aryl, -S(0)o-2-C 6 -Cio-aryl,
• Any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety in Het or Cy is substituted by 1 to 3 substituents selected from the group consisting of halo, -CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-Ce- alkyl)(Ce-Cio-aryl).
• R and R’ is independently selected from H and Ci-Ce-alkyl.
• R and R’ together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S).
• n 0 or 1.
• R 1 is -NO2.
• n is 0. In other embodiments, n is 1.
• X is -NR X (R 2 ). In illustrative embodiments, R x is
• R 2 is selected from the group consisting of -(NR)(Ci-Ce- alkyl)(Het), -(NR)(Ci-Ce-alkyl)(Cy), Cy, and -Ci-Ce-alkyl (optionally substituted with NRR’).
• Cy is a 6- to 12-membered monocyclic or bicyclic carbocyclic ring system.
• Cy can be -Ce-Cio-aryl, such as phenyl or naphthyl.
• Het is a 5- to 12-membered monocyclic or bicyclic heterocyclic ring system.
• the present disclosure also provides in various embodiments an Inhibitor or a pharmaceutically acceptable salt thereof, as set forth in Table 1.
• Table 1 Exemplary Inhibitors
• the disclosure also provides a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of one or more Inhibitors as described herein, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier.
• the pharmaceutical composition further contains, in accordance with accepted practices of pharmaceutical compounding, one or more additional therapeutic agents, pharmaceutically acceptable excipients, diluents, adjuvants, stabilizers, emulsifiers, preservatives, colorants, buffers, flavor imparting agents.
• the pharmaceutical composition comprises a compound selected from those illustrated in Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
• composition of the present disclosure is formulated, dosed, and administered in a fashion consistent with good medical practice.
• Factors for consideration in this context include the particular disorder being treated, the particular subject being treated, the clinical condition of the subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
• the “therapeutically effective amount” of an Inhibitor or a pharmaceutically acceptable salt, stereoisomer, and/or tautomer thereof that is administered is governed by such considerations, and it is the minimum amount necessary to inhibit the interaction between the small GTPase Rab27a and its effector JFC1, inhibit the exocytosis of specific and/or azurophilic granules from neutrophils, reduce a neutrophil inflammatory response, reduce tissue infiltration by neutrophils, and combinations thereof. Such amount may be below the amount that is toxic to normal cells, or the subject as a whole.
• the initial therapeutically effective amount of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure that is administered is in the range of about 0.01 to about 200 mg/kg or about 0.1 to about 20 mg/kg of patient body weight per day, with the typical initial range being about 0.3 to about 15 mg/kg/day.
• Oral unit dosage forms, such as tablets and capsules may contain from about 0.1 mg to about 1000 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In another embodiment, such dosage forms contain from about 50 mg to about 500 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure.
• such dosage forms contain from about 25 mg to about 200 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In still another embodiment, such dosage forms contain from about 10 mg to about 100 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In a further embodiment, such dosage forms contain from about 5 mg to about 50 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In any of the foregoing embodiments the dosage form can be administered once a day or twice per day.
• the Inhibitors of the present disclosure can be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations.
• parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques.
• Suitable oral compositions as described herein include without limitation tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, syrups or elixirs.
• compositions suitable for single unit dosages that comprise a compound of the disclosure or its pharmaceutically acceptable stereoisomer, salt, or tautomer and a pharmaceutically acceptable carrier.
• the Inhibitors of the present disclosure that are suitable for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions.
• liquid formulations of the Inhibitors of the present disclosure can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically palatable preparations of the Inhibitors of the present disclosure.
• the Inhibitors of the present disclosure in admixture with non-toxic pharmaceutically acceptable excipients is used for the manufacture of tablets.
• excipients include without limitation inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known coating techniques to delay disintegration and absorption in the gastrointestinal tract and thereby to provide a sustained therapeutic action over a desired time period.
• a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
• Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
• an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
• an oil medium for example peanut oil, liquid paraffin or olive oil.
• the Inhibitors of the present disclosure is admixed with excipients suitable for maintaining a stable suspension.
• excipients include without limitation are sodium carboxymethylcellulose, methylcellulose, hydroxpropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia.
• Oral suspensions can also contain dispersing or wetting agents, such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
• dispersing or wetting agents such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol,
• the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
• preservatives for example ethyl, or n-propyl p-hydroxybenzoate
• coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
• flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
• sweetening agents such as sucrose or saccharin.
• Oily suspensions may be formulated by suspending the Inhibitors of the present disclosure in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
• the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
• Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide Inhibitors of the present disclosure in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
• Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
• compositions of the present disclosure may also be in the form of oil-in-water emulsions.
• the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
• Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation reaction products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
• the emulsions may also contain sweetening and flavoring agents.
• Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
• Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
• the pharmaceutical compositions may be in the form of a sterile injectable, an aqueous suspension or an oleaginous suspension.
• This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
• the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol.
• the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono-or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• the Inhibitors as described herein may also be administered in the form of suppositories for rectal administration of the drug.
• the Inhibitors can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
• suitable non-irritating excipient include cocoa butter and polyethylene glycols.
• compositions for parenteral administrations are administered in a sterile medium.
• the parenteral formulation can either be a suspension or a solution containing dissolved drug.
• Adjuvants such as local anesthetics, preservatives and buffering agents can also be added to parenteral compositions.
• the Inhibitors described herein can be administered to treat subjects, such as animals in need of such treatment, or who may develop a need for such treatment.
• the Inhibitors can reduce the incidence and severity of diseases associated with systemic neutrophil-dependent inflammation.
• neutrophil-dependent inflammation examples include coronary artery disease, autoinflammatory disease, sepsis, arthritis, ischemia-reperfusion injury, acute lung injury, glomerulonephritis, autoimmune disorders, and cancer.
• the subject is chosen from humans, domesticated animals, zoo animals, and experimental animals.
• Administration of the Inhibitors described herein can reduce the exocytosis of specific and azurophilic granules from neutrophils by at least 10%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70%, or at least 80%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or at least 99%.
• the Inhibitors described herein can reduce neutrophil exocytosis of specific and azurophilic granules by 100%.
• the present disclosure provides a method of treating a disease in a subject suffering therefrom.
• the method comprises administering to the subject one or more Inhibitors or pharmaceutically acceptable salt thereof as described herein.
• the disease is one mediated by neutrophil dysfunction.
• diseases include Coronary Artery Disease, Inflammatory Arthritis, Ischemia-Reperfusion Injury, Autoimmune Disease, Sepsis, Infectious colitis, Ulcerative colitis, Crohn's disease, Ischemic colitis, Radiation colitis, Peptic ulcer, Intestinal, Breast and Ovarian cancer, tumor metastasis (wherein the tumorous disease includes skin squamous cell carcinoma, melanoma, adenocarcinomas, head and neck squamous cell carcinomas (HNSCC), and breast cancer), Intestinal obstruction, Rheumatoid arthritis, Psoriatic arthritis, Hashimoto thyroiditis, Systemic lupus erythematosus, Multiple Sclerosis, Graves’ Disease, Type 1 Diabetes Mellitus, Psoriasis, Ankylosing spondylitis, Scleroderma, Myositis, Gout, Antiphospholipid Antibody Syndrome (APS), Vasculitis, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Re
• Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2 nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2 nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2 nd Ed., John Wiley & Sons, New York, 1992; J.
• Inhibitors Cl Table 1, Inhibitor No. 150
• C2 Table 1, Inhibitor No. 151
• Inhibitors C4 (Table 1, Inhibitor No. 152), C5 (Table 1, Inhibitor No. 153), and C6 (Table 1, Inhibitor No. 154) were prepared by the procedures illustrated in Scheme 2. Scheme 2.
• the coordinate was calculated by using Discovery studio by highlighting binding site residues as previously reported (Johnson, et. al., Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation, J. Bio. Chem. 291 (50): 25965-82 (2016), which is incorporated herein by reference in its entirety).
• the 154 resulting structures from the screen were further screened for Unfavorable Absorption, Distribution, Metabolism, and Elimination (ADME) properties.
• ADME Unfavorable Absorption, Distribution, Metabolism, and Elimination
• the Inhibitors described herein can reduce or prevent inflammation without affecting the initiation of the innate immune response, lack potentially pharmacologically toxic groups, and are optimized for drug likeness and oral bioavailability by filtering potential compounds to comply with at least four out of five of Lipinski’s Rule of Five (RO5) (18):
• Molecular weight (MW) should be less than 500
• Polar surface area should be below 140A 2 .
• a library of Inhibitors was filtered through a rule of three (MW ⁇ 300, HBD ⁇ 3, HBA ⁇ 3 & PSA ⁇ 60A 2 ) SO that the Inhibitors do not violate more than one RO5 rule.
• the Inhibitors were also screened for Pan-assay interference compounds (PAINS) alert (19).
• PAINS Pan-assay interference compounds
• the PAINS parameter can be used to eliminate chemical compounds that non- specifically bind to numerous biological targets.
• FIG. 2C shows the molecular docking analysis of Inhibitor Cl.
• TYR-122 and MET-93 of Rab27a interacts with an aromatic ring of Cl.
• FIG. 2D shows the molecular docking analysis of Inhibitor C2.
• TYR- 122 and MET-93 of Rab27a interacts with an aromatic ring of C2.
• FIG. 2E shows the molecular docking analysis of Inhibitor C4.
• C4 has an aromatic ring substitution which helps make a 7t-alkyl bond with Rab27a binding pocket amino acid ARG-90.
• TYR-122 and MET- 93 of Rab27a also interacts with an aromatic ring of C4.
• FIG. 2F shows the molecular docking analysis of Inhibitor C5.
• TYR-122 and MET-93 of Rab27a interacts with an aromatic ring of C5.
• FIG. 2G shows the molecular docking analysis of Inhibitor C6.
• TYR- 122 and MET-93 of Rab27a interacts with an aromatic ring of C6.
• SER-188 additionally interacts with the heteroaromatic ring of C6.
• Inhibitors Cl, C2, C4, C5, and C6 have Rab27a binding pocket binding energies of -5.4, -5.3, -6.3, -5.4, and -5.2 kcal/mol, respectively.
• Inhibitor C4 has the markedly lower binding energy of -6.3 kcal/mol as compared to the other Inhibitors Cl, C2, C5, and C6 owing to its aromatic substitution and 7t-alkyl bond with Rab27a binding pocket amino acid ARG-90.
• Table I includes the results of the screening for additional Inhibitors 1-149 that have an improved binding energy of less than or equal to a threshold value of -6.5 kcal/mol.
• Example 2 Inhibition of Neutrophil Exocytosis by Inhibitors Cl, C2, C4, C5, and C6.
• FIGs. 3A-C illustrate the effect of Inhibitors Cl, C2, C4, C5, and C6 and comparator Nexinhib 20 (shown as “C20”) on MPO secretion of mouse neutrophils.
• FIG. 3 A is a schematic representation of a cell-based secondary screening assay used to analyze the potency the potency of Rab27a-JFC1 inhibitors for their ability to decrease exocytosis of intact human neutrophil. This cell-based assay measures the secretion of myeloperoxidase (MPO) by human neutrophils using cell-impermeant isoluminol-dependent chemiluminescence in the absence of exogenous peroxidases.
• MPO myeloperoxidase
• Human neutrophils were isolated from normal donor’s blood by Ficoll density centrifugation, as described previously (23).
• Murine bone marrow-derived neutrophils were isolated using a Percoll gradient fractionation system as described (24). A three-layer Percoll gradient was used (52%, 64%, and 72%), and neutrophils were isolated from the 64-72% interface, washed, and used in the assays.
• Extracellular MPO-dependent reactive oxygen species (ROS) production was measured using the chemiluminescence reactions mediated by isoluminol (25). To this end, 3 x 10 5 neutrophils were resuspended in serum -free RPMI 1640 medium in the presence of cell-impermeant isoluminol, and reactions were carried out in the absence of exogenous peroxidase. Neutrophils were incubated in the presence of compounds or DMSO (0.5%) pin- tooled into 384-well plates in a 40-pl volume. Control experiments were run in parallel in the presence of sodium azide (0.5 mM) to inhibit endogenous myeloperoxidase.
• ROS reactive oxygen species
• MPO-dependent chemiluminescence was continuously monitored for 30 min at 37 °C using a 2104 EnVision multilabel plate reader.
• PMA phorbol 12-myristate 13-acetate
• DMSO dimethyl sulfoxide
• FIG. 3B is a graph showing the effect of Inhibitors Cl, C2, C4, C5, and C6 on secreted MPO-dependent reaction using the isoluminol-dependent chemiluminescence assay in highly purified mouse neutrophils.
• the pre-fix “NS” means “no stimuli” where the cells were treated with l OpM Cl, C2, C4, C5, C6, and C20 alone without any exocytosis stimuli.
• the pre-fix “PMA” means the cells were stimulated with PMA to secrete MPO and were treated with I OpM of the designated Inhibitor.
• DMSO was used as a control instead of an Inhibitor and shows the amount of secreted MPO in cells not treated with any Inhibitor.
• Inhibitors Cl, C2, C4, and C6, show significant inhibition of exocytosis by the neutrophils as compared to the DMSO control. Mean % inhibition: Cl, 76.74; C2, 59.85; C4, 70.9; C6, 62.4; C20, 99.22.
• FIG. 3C is a graph of a dose-response analysis of Inhibitor Cl using the chemiluminescence-based MPO secretion assay.
• the graph of FIG. 3C shows a decreasing isoluminol -dependent signal with calculated IC50 value of 0.86 pM indicating that the decrease in exocytosis is a function of treatment with increasing amounts of Cl.
• Example 3 Effect of small molecule inhibitors on exocytosis in human neutrophils.
• the reactions were stopped by transferring the samples to ice and immediately spinning down the cells to initiate blocking and staining.
• the cells were blocked in ice-cold PBS containing 1% BSA and stained with phycoerythrin (PE)-, FITC-, or Alexa647-conjugated anti-human CD63, CD66b, MMP9, and CDl lb antibodies that detect extracellular epitopes of these markers.
• PE phycoerythrin
• FITC- FITC-
• Alexa647-conjugated anti-human CD63, CD66b, MMP9, and CDl lb antibodies that detect extracellular epitopes of these markers.
• the cells were then washed and fixed in 1% paraformaldehyde in PBS. Samples were analyzed using a NovoCyte flow cytometer, and the data were processed using FlowJo software.
• FIG. 4 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of azurophilic granule marker CD63.
• the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of CD63 up-regulation.
• Mean % inhibition Cl, 93.12%; C2, 59.53%; C6, 58.06%.
• FIG. 5 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of specific granule marker CD66b.
• the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of CD66b up-regulation.
• Treatment of the cells with Cl, C2, C4, and C20 all showed marked and significant inhibition of CD66b up-regulation relative to the DMSO control.
• % inhibition Cl, 57.56; C2, 35.81; C4, 48.14; C6 42.33% and C20 100% ANOVA (Sidak’s multiple comparisons test).
• N 12 individual donors.
• FIG. 6 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of Gelatinase granule cargo MMP9.
• the human neutrophils in the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of MMP9 up-regulation.
• N 12 individual donors.
• FIG. 7 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 and also C20 on the mobilization of secretory vesicles by detecting secretory vesicle marker CD1 lb.
• CD1 lb is an adhesion molecule and CD1 lb+ vesicles are readily mobilizable in human polymorphonuclear neutrophils (hPMN).
• hPMN human polymorphonuclear neutrophils
• CD1 lb+ vesicles drive the initiation of the innate immune response.
• the human neutrophils in the DMSO control group treated with GM-CSF and fMLP show the reference amount of CD1 lb+ vesicle release.
• Treatment of the human neutrophils with Inhibitors Cl, C2, C4, C5, and C6 show the release of CD1 lb+ vesicles is unaffected by the small molecule inhibitors relative to the DMSO control.
• the lack of activity of Inhibitors Cl, C2, C4, C5, and C6 on CD1 lb+ vesicles indicates that the Inhibitors can prevent inflammation without affecting the initiation of the innate immune response.
• Treatment of human neutrophils with Nexinhib 20 (C20) show an inhibition of CD1 lb+ vesicle release, indicating that C20 can disrupt the early steps in initiation of the neutrophil innate immune response.
• Mean % Inhibition only C20 significantly inhibited CD1 lb upregulation at the plasma membrane (to levels lower than basal controls). Analysis of the effect of new neutrophil-exocytosis inhibitors in models of systemic inflammation and autoinflammatory disease
• Systemic inflammatory syndromes caused by either genetic defects, exacerbated innate immune responses to infection, trauma or autoimmune disorders are characterized by elevated plasma levels of pro-inflammatory cytokines and by the dysregulated and deleterious activation of the innate immune system, but inhibitors of neutrophil-mediated systemic inflammation are lacking.
• NLRP3 inflammasome has been implicated in numerous common inflammatory disorders (e.g., gout, atherosclerosis, reumathoid arthritis, coronary artery disease and cancer) (Mol Cell 10, 417-426 (2002); Nature 464, 1357-1361, doi: 10.1038/nature08938 (2010)) as well as normal and dysregulated host response to infection (e.g., Streptococcus aureus and malaria).
• the new Nexinhib analogs (NEIa) Cl, C2, C4 and C6 have a selective inhibitory effect on wild-type neutrophils (shown in the provisional filling). These compounds are now tested using neutrophils from a mouse model of Cryopyrin-Associated Periodic Syndrome (CAPS), a systemic inflammatory disease in humans, caused by gain-of-function mutations of the NOD-like receptor family member, cryopirin, also known as NLRP3 (J Clin Immunol 39, 277-286, doi: 10.1007/sl0875-019-00638-z (2019)).
• CPS Cryopyrin-Associated Periodic Syndrome
• Heterozygous NLRP3 mutations lead to hyper-responsive NLRP3 inflammasome function characterized by increased caspase- 1 (Caspl) activation and IL-ip production, and is observed in patients and in animal models with NLRP3 -gain-of-function mutations.
• Nlrp3 ⁇ 550 knockin mouse model of CAPS (MWS CreT,) that phenocopies the disease in humans with the A352V mutation in NLRP3
• NLRP3 dysregulation leads to exacerbated azurophilic granule exocytosis (Johnson, Hoffman and Catz, Cell Infect Microbiol 7, 507, doi: 10.3389/fcimb.2017.00507 (2017).).
• NEIa-Cl, C4-C6 significantly inhibit secretion not only in wild type cells but also in neutrophils that carry the NLRP3 A350V mutation (Fig. 8A-C).
• mice The tamoxifen inducible Nlrp3 k 50N ere ERT2 and control animals were injected (i.p.) with 50 mg/kg tamoxifen free base to induce disease (J Immunol 189, 2707-2711, doi: 10.4049/jimmunol.1101737 (2012)). The mice (6-12 weeks old) had access to food and water ad libitum. All animal studies were performed in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals and according to NIH and institutional guidelines. All animal protocols and procedures were approved by the University of California San Diego Institutional Animal Care and Use Committees (IACUC).
• IACUC Institutional Animal Care and Use Committees
• mice were treated with the neutrophil specific inhibitor NEIa-C6 or vehicle (5% DMSO in PBS).
• NLRP3 ⁇ 550 disease develops progressively in 15 days after first induction with tamoxifen.
• the experimental design is presented in Fig. 9A. Between day 0 and day 5 mice were injected (i.p) every other day with tamoxifen followed by NEIa-C6 (30mg/Kg) or vehicle. Next, administration ofNEIa-C6 or vehicle continued until day 13, in the absence of tamoxifen. Blood samples were obtained at day 7 and blood and tissues harvested at day 13. Treatment with NEIa-C6 did not affect the number of any leukocyte subtype at 7 or 13 days (Fig.
• NEIa- C6 Animals treated with NEIa- C6 were partially protected from weight loss compared to vehicle treated controls (Fig. 9C). Remarkably, NEIa-C6 decreased neutrophil activation in vivo, manifested as the decreased upregulation of the azurophilic and endolysosomal marker CD63 (Fig. 9D). Importantly, treatment with NEIa-C6 also decreased the number of pro-inflammatory immature neutrophils in blood (Fig. 9E). Finally, treatment with NEIa-C6 significantly protected kidneys from neutrophilic infiltration (Fig. 9F). The effect was specific for kidneys as lung and liver infiltration was unaffected (Fig. 9G).
• mice received NEIa-C6 (30mg/Kg) or vehicle by a single i.p. injection and two hours later, the animals are challenged with a single i.p. injection of lipopolysaccharide (LPS, 8 mg/Kg), an important outer membrane component of gramnegative bacteria.
• LPS lipopolysaccharide
• NEIa-C6 cytokine levels in plasma of LPS -insulted and control mice using multiplex technology.
• NEIa-C6 treatment significantly decreases the production of pro- inflammatory cytokines IL-ip and GM-CSF (Fig. 10A).
• NEIa-C6 also decreases the levels of IL-3 (Fig. 10A), a pro inflammatory cytokine that stimulates neutrophils, amplifies acute inflammation and is a potential therapeutic target in sepsis (Science 347, 1260-1265, doi:10.1126/science.aaa4268 (2015)).
• IL-3 deficiency protects mice against sepsis, highlighting NEIa-C6 as a possible agent to combat systemic inflammation in sepsis.
• NEIa-C6 also decreased the levels of MIP-2, an important neutrophil chemoattractant in mice, and IL-17 (Fig. 10A), a mediator of neutrophilic kidney infiltration and renal fibrosis (Am J Physiol Renal Physiol 312, F385- F397, doi: 10.1152/ajprenal.00462.2016 (2017)).
• NEIa-C6 increased the levels of IL-10 which is anti-inflammatory and protective in sepsis (Fig. 10B).
• Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541 (2004).
• Lipinski CA Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacology. Toxicol. Methods. 44: 235-249 (2000).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=90455250

Family Applications (1)

Country Status (2)

Families Citing this family (1)

Family Cites Families (3)

• 2023
  • 2023-09-21 EP EP23869162.0A patent/EP4590300A2/de active Pending
  • 2023-09-21 WO PCT/US2023/074722 patent/WO2024064778A2/en not_active Ceased

Also Published As

Similar Documents

Legal Events